Esophageal Diseases  >>  Vizimpro (dacomitinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vizimpro (dacomitinib) / Pfizer
NCT01608022: A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
48
RoW
PF804
Yonsei University
Esophageal Squamous Cell Carcinoma
04/15
10/15

Download Options